Efficacy and safety of olmesartan medoxomil‑amlodipine besylate tablets (Sevikar<sup>®</sup>) in older patients with essential hypertension: Subgroup analysis from the Sevikar study.

Authors:
Cui Z; Qiu Z; Cheng W; Hu W; Ma G and 35 more

Journal:
Exp Ther Med

Publication Year: 2023

DOI:
10.3892/etm.2023.12338

PMCID:
PMC10790165

PMID:
38234624

Journal Information

Full Title: Exp Ther Med

Abbreviation: Exp Ther Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, Research & Experimental

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests JD, LW and MLi are employees of Daiichi Sankyo (China) Holdings Co., Ltd., the company that makes SVK. The other authors declare that they have no competing interests."

Evidence found in paper:

"Funding: The present study was supported by Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025